129 related articles for article (PubMed ID: 22773127)
21. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
22. Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma.
Weaver CH; Zhen B; Schwartzberg LS; Leff R; Magee M; Geier L; Deaton K; Lewkow L; Buckner CD
Bone Marrow Transplant; 1998 Aug; 22(3):245-51. PubMed ID: 9720737
[TBL] [Abstract][Full Text] [Related]
23. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy.
Tricot G; Barlogie B; Zangari M; van Rhee F; Hoering A; Szymonifka J; Cottler-Fox M
Haematologica; 2008 Nov; 93(11):1739-42. PubMed ID: 18728024
[TBL] [Abstract][Full Text] [Related]
24. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
25. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.
Hart C; Grassinger J; Andreesen R; Hennemann B
Bone Marrow Transplant; 2009 Feb; 43(3):197-206. PubMed ID: 18806833
[TBL] [Abstract][Full Text] [Related]
26. [Autologous stem cell transplantation in multiple myeloma - pro].
Goldschmidt H
Dtsch Med Wochenschr; 2009 Sep; 134(39):1942. PubMed ID: 19760555
[No Abstract] [Full Text] [Related]
27. Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial.
Gupta S; Zhou P; Hassoun H; Kewalramani T; Reich L; Costello S; Drake L; Klimek V; Dhodapkar M; Teruya-Feldstein J; Hedvat C; Kalakonda N; Fleisher M; Filippa D; Qin J; Nimer SD; Comenzo RL
Bone Marrow Transplant; 2005 Mar; 35(5):441-7. PubMed ID: 15640822
[TBL] [Abstract][Full Text] [Related]
28. Use of sidestream dark-field (SDF) imaging for assessing the effects of high-dose melphalan and autologous stem cell transplantation on oral mucosal microcirculation in myeloma patients.
Milstein DM; te Boome LC; Cheung YW; Lindeboom JA; van den Akker HP; Biemond BJ; Ince C
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jan; 109(1):91-7. PubMed ID: 20123381
[TBL] [Abstract][Full Text] [Related]
29. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
Lilleby K; Garcia P; Gooley T; McDonnnell P; Taber R; Holmberg L; Maloney DG; Press OW; Bensinger W
Bone Marrow Transplant; 2006 Jun; 37(11):1031-5. PubMed ID: 16633359
[TBL] [Abstract][Full Text] [Related]
30. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
31. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
[TBL] [Abstract][Full Text] [Related]
32. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Child JA; Morgan GJ; Davies FE; Owen RG; Bell SE; Hawkins K; Brown J; Drayson MT; Selby PJ;
N Engl J Med; 2003 May; 348(19):1875-83. PubMed ID: 12736280
[TBL] [Abstract][Full Text] [Related]
33. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
[TBL] [Abstract][Full Text] [Related]
34. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
Sanchorawala V; Wright DG; Quillen K; Finn KT; Dember LM; Berk JL; Doros G; Fisher C; Skinner M; Seldin DC
Bone Marrow Transplant; 2007 Sep; 40(6):557-62. PubMed ID: 17589534
[TBL] [Abstract][Full Text] [Related]
35. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents.
Lerro KA; Medoff E; Wu Y; Seropian SE; Snyder E; Krause D; Cooper DL
Bone Marrow Transplant; 2003 Dec; 32(12):1113-7. PubMed ID: 14647264
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study.
Uy GL; Goyal SD; Fisher NM; Oza AY; Tomasson MH; Stockerl-Goldstein K; DiPersio JF; Vij R
Bone Marrow Transplant; 2009 May; 43(10):793-800. PubMed ID: 19029964
[TBL] [Abstract][Full Text] [Related]
37. High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma.
Bishton M; Gilyead M; Das Gupta E; Williams C; Russell NH; Byrne JL
Leuk Res; 2007 Aug; 31(8):1063-8. PubMed ID: 17324463
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation.
Bleeker JS; Gertz MA; Pellikka PA; Larson DR; Buadi F; Dingli D; Dispenzieri A; Hayman SR; Hogan W; Kumar S; Rajkumar SV; Lacy MQ
Eur J Haematol; 2012 Sep; 89(3):228-35. PubMed ID: 22672722
[TBL] [Abstract][Full Text] [Related]
39. Role of CD34+ cells in engraftment after high-dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue.
Millar BC; Millar JL; Bell JB; Raje N; Milan S; Mehta J; Singhal S; Middleton GW; Sheperd V; Catovsky D; Powles RL
Bone Marrow Transplant; 1996 Nov; 18(5):871-8. PubMed ID: 8932839
[TBL] [Abstract][Full Text] [Related]
40. Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients.
Palumbo A; Triolo S; Baldini L; Callea V; Capaldi A; De Stefano V; Grasso M; Liberati M; Lotesoriere C; Marcenò R; Marmont F; Musto P; Petrucci MT; Spriano M; Pileri A; Boccadoro M
Haematologica; 2000 May; 85(5):508-13. PubMed ID: 10800168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]